One ALS patient received TRE-515 under the FDA program last year, and early signs suggest the therapy may help stabilize ...

ALS patients and caregivers prefer care models where multiple specialists are seen during the same visit. They prioritize team-based care and ALS expertise over factors like visit length or cost.

ALS is life‑changing, but new treatments, specialized care, and innovative research are bringing real hope. See how advances at University of Utah Health are shaping the future of ALS care.

Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer, ...

Joe Redmond has outlived his prognosis by years and now volunteers as a 'Pathfinder' to guide newly diagnosed patients ...

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder that is thought to have a significant link to ...

The PREVAiLS study, believed to be the only recruiting phase 3 ALS trial, aims to slow disease progression and preserve ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Researchers have found that patients with amyotrophic lateral sclerosis have ...

Eric Dane not only battled ALS, but also advocated for others fighting the disease before his death. Dane’s work as an ALS ...

Columbia's Silence ALS program is testing spinal antisense therapy in a high‑risk patient; early EMG tests normalized.

ALS patient Kenneth Shock has regained his ability to speak using a Neuralink voice implant, which converts his thoughts into speech. The brain-computer interface allows him to communicate in his ...

Michael Podolsky, a 44-year-old man diagnosed with amyotrophic lateral sclerosis (ALS), died on September 25 at Sheba Medical Center in Tel HaShomer after a Tel Aviv District Court granted his request ...